|Home | About | Journals | Submit | Contact Us | Français|
EDP-239, a novel hepatitis C virus (HCV) inhibitor targeting nonstructural protein 5A (NS5A), has been investigated in vitro and in vivo. EDP-239 is a potent, selective inhibitor with potency at picomolar to nanomolar concentrations against HCV genotypes 1 through 6. In the presence of human serum, the potency of EDP-239 was reduced by less than 4-fold. EDP-239 is additive to synergistic with other direct-acting antivirals (DAAs) or host-targeted antivirals (HTAs) in blocking HCV replication and suppresses the selection of resistance in vitro. Furthermore, EDP-239 retains potency against known DAA- or HTA-resistant variants, with half-maximal effective concentrations (EC50s) equivalent to those for the wild type. In a phase I, single-ascending-dose, placebo-controlled clinical trial, EDP-239 demonstrated excellent pharmacokinetic properties that supported once daily dosing. A single 100-mg dose of EDP-239 resulted in reductions in HCV genotype 1a viral RNA of >3 log10 IU/ml within the first 48 h after dosing and reductions in genotype 1b viral RNA of >4-log10 IU/ml within 96 h. (This study has been registered at ClinicalTrials.gov under identifier NCT01856426.)
Chronic infection with the hepatitis C virus (HCV) is a major global health burden, infecting approximately 3.5 million individuals in the United States (1) and up to 150 million worldwide (2). HCV is estimated to infect approximately 3 to 4 million people each year, with a prevalence in the United States estimated at 1.3% (1) and prevalences as high as 22% in Egypt, 4.8% in Pakistan, and 3.2% in China (3). Chronic HCV infection can lead to cirrhosis of the liver and hepatocellular carcinoma, contributing to the deaths of 700,000 individuals each year (3).
HCV is an enveloped, single-stranded, positive-sense RNA virus in the family Flaviviridae. The ~9.6-kb genome is translated into a single polyprotein that is subsequently processed into at least 10 structural and nonstructural proteins that are necessary for replication of viral RNA and assembly of new virions (4). At least six distinct HCV genotypes (GTs) and more than 50 subtypes have been characterized, with significant variability in their geographic distributions (5).
Within the past 5 years, treatment options for HCV infection have improved dramatically, with approvals from the U.S. Food and Drug Administration for sofosbuvir, ledipasvir, daclatasvir, ombitasvir, paritaprevir, dasabuvir, simeprevir, grazoprevir, and elbasvir. However, it is becoming apparent that differences in potency among the existing approved drugs against various HCV genotypes, as well as their associated resistant variants, demonstrate a clear unmet medical need for additional approved therapies. EDP-239, a small-molecule inhibitor targeting the nonstructural protein 5A (NS5A) of HCV, was designed to address this unmet need.
NS5A is a nonstructural HCV protein, with no known enzymatic activities, and is an essential component of the HCV replication complex (6). NS5A possesses RNA binding activity and is comprised of an amphipathic α-helix (amino acids 5 to 25) that is important for membrane localization, followed by three distinct structural domains (7,–9). Domain I (amino acids 37 to 213) is essential for viral replication, possesses a zinc binding motif, and has been crystallized as a homodimer (9, 10). Domains II (amino acids 250 to 342) and III (amino acids 356 to 447) are less well characterized and exist in a natively unfolded conformation (11, 12). Current evidence indicates that the NS5A protein is essential not only for genome replication but also for the assembly of infectious virions (13). Given its involvement in multiple stages of the viral life cycle, NS5A is an attractive target for small-molecule inhibition. Clinically, rapid and profound reductions of HCV RNA have been observed following monotherapy with several other NS5A inhibitors, including daclatasvir, ledipasvir, ACH-3102, and PPI-668 (14,–17).
EDP-239 is a novel NS5A inhibitor with half-maximal effective concentrations (EC50s) in vitro of 31 and 7 pM against genotype 1a (GT1a) and GT1b replicons, respectively. In this report, we demonstrate that EDP-239 does not experience a reduction in potency against replicons resistant to other host-targeted antivirals (HTAs) and direct-acting antivirals (DAAs). In combination experiments, EDP-239 was additive to synergistic with other DAAs or HTAs in inhibiting HCV replication, and apparent combination effects suppressed the selection of HCV resistance in vitro following persistent treatment of replicon cells. Insights gained from the in vitro data presented here were used to guide the clinical development of EDP-239. A phase Ib proof-of-concept study was initiated to determine the efficacy of a single dose of EDP-239, and some of the clinical results are reported here.
The chemical reagents used in this study were EDP-239, alisporivir (CAS number 1190307-88-0), daclatasvir (CAS number 1009119-64-5), GSK625433 (CAS number 885264-71-1), simeprevir (CAS number 923604-59-5), and sofosbuvir (CAS number 1190307-88-0), which were synthesized by the chemistry department at Enanta Pharmaceuticals. Dimethyl sulfoxide (DMSO) was used as the solvent for these chemicals. Human interferon alpha 2A was purchased from Sigma (CAS number 105388-21-4) and diluted in sterile phosphate-buffered saline (PBS).
Vero, MDBK, MRC-5, HEK293, and Raji cells were obtained from the ATCC and cultured according to ATCC recommendations. Human hepatoma cells (Huh7 Lunet and derivatives) were obtained from ReBLikon GmbH and maintained in complete Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 1% Glutamax (Life Technologies), 1% penicillin-streptomycin (Life Technologies), and 1% nonessential amino acids solution (MEM NEAA; Life Technologies). Huh7 Lunet cells, described previously (18), were used as host cells for replicon transient transfections and subsequent assays. Several stably transfected subgenomic replicon cell lines were used for compound characterization in cell culture: GT1a replicon cell line En5-3 (19) (Stan Lemon, UNC) and GT1b replicon cell lines Huh-luc/neo-ET and Huh SGR11-7 (18, 20) (ReBLikon, GmbH) were maintained in complete DMEM additionally supplemented with 0.25, 0.5, or 0.75 mg/ml Geneticin, respectively.
The GT1a replicon clone expressed in En5-3 cells, Htat2ANeo/QR/VI/KR/KR5A/SI (19), was modified by first removing the XbaI site from the luc-ubi-neo cassette in the GT1b replicon construct I389luc-ubi-neo/NS3-3′/ET (ReBLikon GmbH) prior to exchanging it for the Htat2ANeo cassette. The resulting LucUbiNeo/QR/VI/KR/KR5A/SI construct was reverse transcribed, and RNA was stably transfected into Huh7 Lunet cells, as previously described (21), to create Huh1a-Luc cells.
GT2a, GT3a, and GT4a replicon cell lines JFH1/SG-Feo, S52/SG-Feo (SH), and ED43/SG-Feo (VYG), respectively (22), were obtained from Apath and maintained in complete DMEM described above and supplemented with 0.75 mg/ml Geneticin. HCV RNA was isolated from the sera of patients infected with HCV GT3a, GT4a, and GT5a and was amplified by reverse transcription (RT)-PCR to generate a DNA fragment encoding either the first 100 amino acids of NS5A (100) or the full-length protein (FL). Chimeric GT1b/3a (FL), GT1b/4a (FL), and GT1b/5a (100) luciferase reporter replicon constructs were subsequently created. Briefly, a unique SbfI restriction enzyme site followed by a stop codon was first engineered by site-directed mutagenesis into the 5′ end of the GT1b wild-type NS5A gene within the I389luc-ubi-neo/NS3-3′/ET replicon construct (ReBLikon GmbH) to create an I389luc-ubi-neo/NS3-3′/ET-SbfI-stop construct. Patient isolate DNA fragments encoding the first 100 amino acids were molecularly stitched by PCR to amplified DNA encoding the last 347 amino acids of GT1b NS5A plus the first 88 amino acids of NS5B. DNA fragments encoding the full-length NS5A or chimeric stitched DNA fragments were subsequently digested using PstI (site included in 5′ primer) and BclI. The digested fragments were ligated into an I389luc-ubi-neo/NS3-3′/ET-SbfI-stop replicon construct that had been predigested with SbfI and BclI. Ligation of the insert into the vector removed the previously introduced stop codon and eliminated the SbfI site. The ligated plasmid was transformed into Escherichia coli by chemical transformation and amplified in liquid culture. The final sequence was confirmed by DNA sequence analysis. HCV GT6a testing was performed by WuXi AppTec, Inc., using a GT1b (Con1) chimeric replicon expressing GT6a NS5A (full-length strain 6a61; GenBank accession number DQ480516).
Amino acid mutations reported to confer resistance to inhibitors of the NS3, NS5A, and NS5B proteins (14, 21, 25, 26) were created by introducing substitutions into the GT1b (Con1, I389luc-ubi-neo/NS3-3′/ET) HCV replicon bicistronic clone using site-directed mutagenesis (Stratagene QuikChange XL II) and standard cloning methods. The presence of each mutation was confirmed by sequence analysis. Prior to in vitro transcription of replicon RNA, each plasmid was linearized by digestion with AseI and ScaI. The HCV subgenomic RNA was transiently transfected via chemical transfection into Huh7 Lunet cells using DMRIE-C (Invitrogen) reagent as described previously (21), with modifications. Briefly, Huh7 Lunet cells were seeded at 106 cells per 10-cm tissue culture plate in transfection seed medium (DMEM supplemented with 10% charcoal dextran-stripped fetal bovine serum [FBS] and 1% MEM NEAA) and incubated overnight at 37°C, in 5% CO2. Replicon RNA (15 μg) was diluted in 6 ml DMEM (no supplements) plus 60 μl DMRIE-C reagent. Each overnight 10-cm cell culture was washed twice in DMEM, and each diluted RNA sample was added to one plate and incubated for 3.5 h at 37°C, in 5% CO2. Plates were subsequently washed twice with DMEM, followed by the addition of 10 ml complete DMEM (described above). Transfected cells were incubated overnight at 37°C, in 5% CO2, and seeded the following day at 5,000 cells/well on white 96-well plates (assay plate) in 100-μl/well assay medium (assay medium is DMEM without phenol red, supplemented with 10% FBS, 1% penicillin-streptomycin, 1% MEM NEAA, and 1% Gluta MAX-1). Assay plates were incubated overnight at 37°C, in 5% CO2. The following day, compounds previously titrated in DMSO were diluted 1,000-fold when added to each assay plate (0.1% DMSO final concentration). Each assay plate was subsequently incubated for 72 h at 37°C, in 5% CO2, and then 100 μl/well BriteLite Plus (PerkinElmer) was added and the luminescence was read with an EnVision Excite multilabel plate reader (PerkinElmer). Inhibition of luciferase expression, a measure of viral replication, was determined, and EC50s were calculated by fitting the inhibition data to a four-parameter logistical model using XLfit.
For cytotoxicity measurements, cell lines were seeded at approximately 30% confluence and incubated in the presence of 1,000-fold-diluted compounds (previously titrated in 2- or 3-fold dilutions in DMSO) for 72 h at 37°C, in 5% CO2, and then 60 μl/well ATPlite (PerkinElmer) was added and the luminescence was read with an EnVision Excite multilabel plate reader.
Huh1a-Luc cells were seeded in assay medium (described above) at 5,000 cells/well on white (for viral inhibition assay) or black (for proliferation inhibition assay) 96-well assay plates and incubated overnight at 37°C, in 5% CO2. Compound master plates were prepared, with each compound titrated in DMSO in an x or y direction in an 8-point 2-fold dilution curve with the 90% effective concentration (EC90) used as a top concentration. x and y direction master plates were diluted 100-fold in assay medium and then an additional 10-fold onto each assay plate for a final compound dilution of 1:1,000, generating an 8 × 8 (64-point) dose-response combination matrix. The cells were then incubated for 72 h before the measurement of luciferase activity (viral inhibition) or ATP reduction (cell viability). BriteLite Plus was added to each white viral inhibition assay plate, and ATPlite (PerkinElmer) was added to each black cell viability assay plate, according to the manufacturer's directions. All luminescence measurements were assayed, as described above, using an EnVision Excite multilabel plate reader. Compound combinations were assessed in biological quadruplicate dose matrices, and DMSO or PBS (interferon) control wells were included as negative, untreated controls. The combinations were analyzed for synergy, additivity, or antagonism using either the Loewe additivity model and quantified by the combination index (CI) using CalcuSyn software from Biosoft (24) or the Bliss additivity model, determined using MacSynergy II (23).
Resistance suppression combinations were performed by seeding En5-3 (GT1a) or Huh11-7 (GT1b) cells on 6-well plates at subconfluence. Compounds were diluted in DMSO and applied as single agents or in combination every 3 days to growth medium containing G418 for approximately 2 weeks. Two independent experiments per treatment were conducted with 6-well plates. Cells were incubated with compound until the control samples (0.2% DMSO) reached confluence. Cells were subsequently passaged 1:12 onto fresh 6-well plates and continuously cultured until macroscopic colonies were visible and G418-sensitive cells had died. The cells were subsequently fixed and stained with 1% crystal violet in 70% ethanol.
EDP-239 was investigated in a randomized, double-blind, placebo-controlled, parallel-cohort multicentered study (ClinicalTrials.gov registration no. NCT01856426). The study was approved by the institutional review boards at all study centers and conducted in accordance with good clinical practice and ethical principles. Twenty-eight male and female patients with chronic GT1 HCV infection were enrolled. The study was stratified by equal numbers of subjects infected with HCV GT1a and GT1b and randomized into 1 of 5 treatment arms to receive single doses of EDP-239 or placebo. In all patients, a single dose of EDP-239 or placebo was administered (time zero, day 1). Doses of EDP-239 in individual treatment arms were as follows: 10, 30, 100, and 200 mg. Each EDP-239 treatment cohort was intended to have 6 patients, with 2 patients from each cohort receiving placebo. One patient's HCV genotype was incorrectly identified as GT1b prior to receipt of the first dose; subsequent sequencing analysis and confirmatory genotyping near the end of the study indicated that the patient was infected with GT1a HCV. Plasma samples for determining HCV RNA levels were drawn at screening, prior to the first dose on day 1 (baseline), at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 216, and 312 h after the initial dose, and on weeks 12, 24, and 48. HCV RNA levels were measured by Covance, Inc., using the Roche COBAS TaqMan HighPure HCV v2.0 assay, with a lower limit of quantification of 25 IU/ml.
Patient blood (plasma) samples for analysis of EDP-239 concentrations were collected on day 1 before dosing (time zero) and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, and 120 h after dosing. Plasma samples were analyzed by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for determination of EDP-239 concentrations. The resulting data underwent analysis, whereby pharmacokinetic (PK) parameters of EDP-239 were determined using the actual recorded sampling times and a noncompartmental approach consistent with the oral route of administration. WinNonlin Pro (Pharsight Corporation, St. Louis, MO; version 5.2 or higher) was used for PK analysis with the following parameters determined from the plasma concentration-time data: maximum concentration of drug in serum (Cmax), time to maximum concentration of drug in serum (Tmax), area under the concentration-time curve from zero to infinity (AUC0–inf), half-life (t1/2), and the apparent total clearance of drug from plasma after oral administration (CL/F).
The chemical structure of EDP-239 is shown in Fig. 1. EDP-239 is a potent inhibitor of multiple HCV genotypes, with EC50s of 4 to 394 pM for GT1a, -1b, -4a, -5a, and -6a, respectively, and EC50s of 5 to >50 nM for GT2a and -3a, respectively (Table 1). In the presence of 40% human serum, the potency of EDP-239 was reduced by 3.8- and 2.7-fold against GT1a and GT1b, respectively. In cytotoxicity assays using multiple cell lines, EDP-239 did not inhibit cell proliferation significantly (>50% growth inhibition) at concentrations up to 10 μM during a 3-day exposure. Thus, in vitro selectivity indexes (50% cytotoxic concentration [CC50]/EC50) of >320,512 and >1,369,863 were calculated for GT1a replicon cells and GT1b replicon cells, respectively, in the absence of 40% human serum. The results of these experiments establish that EDP-239 is a potent, selective inhibitor of subgenomic HCV replication in cell culture assays.
Antiviral compounds targeting specific viral proteins can select for mutations that lead to reduced potency of that compound and can also result in decreased susceptibility to other antiviral compounds of a similar class. While less common, the effectiveness of compounds targeting different proteins within the same protein complex may also be affected by mutations in an off-target protein. Therefore, we sought to investigate the impact of resistance-associated mutations (RAMs) previously identified within the NS3, NS5A, and NS5B proteins of HCV on EDP-239 potency (Table 2) (25,–29; M. Gao, R. Fridell, D. O'Boyle, D. Qiu, J. Sun, J. Lemm, P. Nower, L. Valera, S. Voss, M. Liu, M. Belema, V. Nguyen, J. Romine, S. Martin, M. Serrano-Wu, D. St Laurent, L. Snyder, R. Colonno, L. Hamann, and N, Meanwell, presented at the 15th International Symposium on Hepatitis C Virus and Related Viruses, San Antonio, TX, 5–9 October 2008). GT1b replicons expressing amino acid substitutions that confer resistance to NS3 protease (R155K or D168V), NS5B polymerase (M414T or S282T), or cyclophilin inhibitors (D320E in NS5A) are not cross-resistant to EDP-239, as demonstrated by the lack of potency shifts observed against these HCV RAMs. However, it is apparent that EDP-239 potency is reduced by NS5A RAMs (Y93H, L31M, or L31V) selected by similar classes of approved NS5A inhibitors such as ledipasvir or daclatasvir (21, 28). EDP-239 was less sensitive to Y93H and L31M resistance mutations than daclatasvir, experiencing 22- and 2-fold EC50 increases, respectively, compared to 89- and 36-fold EC50 increases for daclatasvir. The L31V RAM was determined to confer a higher degree of resistance (20-fold) against EDP-239 than against daclatasvir (5-fold). A more detailed analysis of RAMs selected in vitro in GT1a and GT1b replicon cells, as well as an analysis of these data in the context of clinical RAMs identified in the phase I clinical trial, are reported in an accompanying article (29).
Given the encouraging data regarding the lack of cross-resistance between EDP-239 and RAMs selected by protease, cyclophilin, or polymerase inhibitors, we sought to assess the possible benefits associated with EDP-239 in combination with other DAA or HTA compounds. Two types of combination studies were conducted to identify combination effects following either transient or persistent treatment of replicon cells.
First, EDP-239 and other HTA or DAA compounds were titrated in an x or y direction, generating an 8-point, 2-fold dilution curve with the EC90 used as a top concentration. Combinations of EDP-239 with simeprevir (protease inhibitor), sofosbuvir (nucleoside inhibitor), alisporivir (cyclophilin inhibitor), or interferon alpha (IFN) were then added to Huh1a-Luc replicon cells. The inhibition of luciferase, a measure of viral replication, was determined for each combination. The combination data were analyzed for antagonistic, additive, or synergistic combination effects across the entire combination surface created by the diluted compounds by using two separate metrics for quantifying additivity.
The predicted additive effects for each combination were first calculated using the Bliss independence additivity model (I = IX + IY − IXIY), where IX and IY are the single-agent inhibition levels at concentrations X and Y (30). This model is employed by the MacSynergy program (23) and is a frequently used additivity model that allows additivity to be calculated from minimally sampled experiments. Despite its popularity, it remains a poor predictor of dose additivity between combinations of the same drug, and thus its relevance to combinations of drugs in biological settings is questionable. Nevertheless, Fig. 2 represents the differences (within 95% confidence intervals) between experimental inhibition effects and predicted Bliss independence additive effects for each combination matrix. A positive value in excess of the predicted additivity is considered synergistic, while a negative value is considered antagonistic. The effects of EDP-239 in combination with all antivirals tested were either at or exceeded the levels predicted by the Bliss independence model for EDP-239 in combination with other DAAs or HTAs, suggesting additive to synergistic inhibition of HCV replication. There was no significant antagonism or cytotoxicity (data not shown) observed for any of the combinations of compounds.
The Loewe additivity model (31) represents the expected combination response if both agents are actually the same compound. Deviations from Loewe additivity are quantified by using the combination index (CI), which is essentially a ratio of the total combined concentration to each of the constituent concentrations required to achieve the specified effect level, and was determined using the CalcuSyn program (24). When the combination inhibition data were evaluated in the context of the Loewe additivity model, CI scores were calculated for five separate ratios of each combination matrix and at four separate effective concentrations (EC50, EC75, EC90, EC95). The CI scores for each effective concentration were averaged across the multiple ratios and are shown in Table 3. A CI score of >1.1 can generally be considered indicative of antagonism, while scores between 0.9 and 1.1 signify additivity and scores less than 0.9 indicate synergy. For reference, a CI of 0.5 indicates that the total molar concentration of the combination to achieve a given effect level is only half what is needed for either of the single agents alone. All of the combinations tested with EDP-239 were generally found to be additive to synergistic by the Loewe additivity model. In particular, combinations of EDP-239 with alisporivir, simeprevir, and sofosbuvir tended toward significant synergy at concentrations achieving an EC75, EC90, or EC95. Interactions between EDP-239 and interferon alpha were calculated as additive at all effective concentrations. The CI values tended toward additivity for combinations with simeprevir at concentrations achieving an EC50, but these concentrations were lower than those that would be of clinical interest.
Combination studies were also conducted in vitro using GT1b replicons with similar results (data not shown). Given that infection with GT1a in patients has proven more difficult to treat than infection with GT1b, GT1a was highlighted for these combination studies. Future studies aimed at additional genotypes will be conducted prior to subsequent clinical testing.
In an effort to determine if combination effects between EDP-239 and a DAA or an HTA are also apparent following persistent treatment of replicons, combinations of EDP-239 and sofosbuvir or alisporivir were applied to replicon cells at the fold increases in concentration indicated above each compound's EC50 in Fig. 3. Persistent combination effects were apparent for either dose of EDP-239 in combination with sofosbuvir at 5× or 10× its EC50 in GT1a replicon cells, resulting in suppression of resistant colonies. EDP-239 in combination with alisporivir produced even more dramatic combination effects in GT1b replicon cells, with all combination doses of EDP-239 and alisporivir completely suppressing the expansion of drug-resistant colonies. These results demonstrate that transient EDP-239 synergy with DAAs or HTAs translates to combination effects observed with persistent treatment, where combinations of EDP-239 and DAAs were more effective in suppressing the selection of resistant clones than either agent alone.
We sought to determine whether the favorable preclinical characteristics of EDP-239 translate to the clinic by conducting a placebo-controlled proof-of-concept study of four cohorts comprised of six GT1 HCV-infected patients each. Following a single dose of EDP-239, mean concentrations in plasma reached a peak (Tmax) at approximately 2 to 3 h, followed by a biphasic decrease in concentration over 120 h (Table 4). AUC0–inf and Cmax values displayed dose-dependent increases. It appears that the increase in exposure was somewhat greater than dose proportional toward the highest dose of 200 mg, consistent with a lower apparent clearance (CL/F) when the dose increased from 100 to 200 mg. The terminal elimination half-life (t1/2) was essentially unchanged at approximately 23 to 25 h across all 4 doses, supporting once daily dosing.
Administration of a single dose of EDP-239 resulted in rapid reductions in GT1a and GT1b HCV RNA levels at all doses tested (10, 30, 100, and 200 mg), with viral loads reaching the nadir at either day 2 or 3 in GT1a patients (Fig. 4A) or at days 3 to 5 in GT1b patients (Fig. 4B). Within the first 24 h of receiving a single dose of EDP-239, mean reductions in GT1a HCV RNA levels were ≥2 log10 IU/ml in patients receiving 10 or 30 mg of compound. In patients receiving 100 mg of EDP-239, the mean reduction in GT1a RNA levels within 24 h was 3.4 log10 IU/ml. A comparable mean reduction was observed for patients receiving 200 mg EDP-239 but only if the results for one patient were excluded from the mean calculation. This patient passed the inclusion criteria for this study with a plasma HCV RNA concentration of 4.4 × 105 IU/ml at screening. However, prior to receiving a single dose of EDP-239 on day 1, this patient's viral RNA level at baseline had decreased by more than 15-fold to 2.5 × 104 IU/ml, below the limit (105 IU/ml) imposed for inclusion. It is additionally noteworthy that genotyping results initially categorized another patient as a GT1b patient prior to dosing with 10 mg EDP-239; however, subsequent sequencing results and repeat genotype testing confirmed that this patient was actually infected with a GT1a virus.
GT1b viral RNA reductions in infected patients were even more rapid than in GT1a patients (Fig. 4B). Within the first 24 h, mean reductions in GT1b HCV RNA levels were >2.9 log10 IU/ml in patients in all dose cohorts. Viral RNA levels continued to decline over the subsequent 1 to 3 days, with a maximum mean decline in HCV RNA of >4 log10 IU/ml in patients receiving 100 mg of compound and of ≥3.5 log10 IU/ml in patients receiving 10-, 30-, and 200-mg doses. In addition, HCV RNA suppression was more sustained in GT1b patients, and in patients receiving 100 mg EDP-239, RNA concentrations did not rebound until 216 h postdosing.
Maximum HCV RNA reductions were determined for all patients in each dose cohort by HCV genotype and compared to the mean reductions in viral RNA by dose cohort (Fig. 5). Because the patient sample size in each cohort was small, we employed a two-tailed Student's t test to determine the statistical significance of the RNA reductions by dose. Our statistical analysis found that the 100-mg and 200-mg doses in GT1a patients (Fig. 5A) are significantly more efficacious (P = 0.05 and P = 0.02, respectively) than the 10-mg dose (Fig. 5A), but no statistically significant differences were observed between the dose cohorts in GT1b HCV-infected patients (Fig. 5B). A comparison of the dose cohorts between genotypes 1a and 1b found that only the 10-mg dose is statistically more efficacious in GT1b patients than in GT1a patients (P < 0.01).
Maximum mean HCV RNA reductions (Table 5) from baseline for the GT1a cohort were as follows (in log10 IU/ml): 0.20 (day 4) for placebo, 2.08 (day 2) for 10 mg, 2.32 (day 2) for 30 mg, 3.58 (day 3) for 100 mg, and 3.39 (day 3) for 200 mg (excluding the patient with a baseline HCV RNA level of <105 IU/ml). Maximum mean reductions from baseline for the GT1b cohort were as follows (in log10 IU/ml): 0.17 (day 3) for placebo, 3.90 (day 4) for 10 mg, 3.50 (day 3) for 30 mg, 4.36 (day 5) for 100 mg, and 3.80 (day 5) for 200 mg. In general, HCV RNA suppression was more sustained in GT1b patients than in GT1a patients, which is consistent with the previously defined differences in potency for EDP-239 against GT1a and GT1b replicons in vitro.
EDP-239 is a novel, potent, and selective inhibitor of HCV replication in vitro with low cellular toxicity. EDP-239 has no significant activity against the NS3 serine protease or NS5B polymerase (data not shown). Resistance selection studies in vitro identified numerous changes within the first 100 amino acids of NS5A (29). Selection of these resistance-associated mutations in the NS5A gene further supports the hypothesis that EDP-239 interferes with HCV replication by inhibiting NS5A function. Additional analyses concerning RAMs selected in vitro and whether they are predictive of baseline or treatment-emergent mutations in vivo will be reported elsewhere (29). Here, we provide evidence of the compound's potency in numerous in vitro preclinical assays as well as its potential suitability for future development as a therapeutic to be used in combination with existing HCV antivirals. We also demonstrate the clinical efficacy of EDP-239 in GT1 HCV-infected patients and discuss the contribution of its improved pharmacokinetics to the observed clinical results.
EDP-239 inhibits HCV subgenomic replicon replication, with activity at picomolar concentrations against genotypes 1a, 1b, 4a, 5a, and 6a and potency at nanomolar concentrations against genotypes 2a and 3a. This genotypic potency profile is not dissimilar to reports of another NS5A inhibitor, ledipasvir, which has comparable potencies against similar genotypes (32). However, in a phase I clinical study of ledipasvir, there were no significant differences in HCV RNA reduction between GT1a and GT1b patients receiving three daily 10-mg doses of study drug nor were there discernible dose effects among GT1a patients receiving 10, 30, or 90 mg despite clear dose-dependent drug exposures (15). We report here statistically significant EDP-239 potency differences between GT1a and GT1b patients receiving a single 10-mg dose of study drug, as well as significant dose effects observed in GT1a patients receiving 100- and 200-mg single doses of EDP-239 in comparison to the 10-mg dose cohort. The lack of significant dose effects in GT1b patients is the result of viral RNA concentrations suppressed to levels near the limit of quantification in patients treated with all four doses. These results are consistent with in vitro data demonstrating greater EDP-239 potency against GT1b than against GT1a.
Previous clinical analyses of ledipasvir found that maximal concentrations (Cmax) achieved in patients with 10-, 30-, or 90-mg doses were 18.7, 67.0, and 166.5 ng/ml, respectively, on day 1. In contrast, maximal concentrations of EDP-239 described here were 4- to 5-fold higher with comparable doses. The apparent greater exposures for EDP-239 likely led to the continued decline in HCV RNA concentrations described here, achieving a maximum reduction 48 h after dosing in GT1a patients receiving 100 or 200 mg and up to 96 h later in GT1b patients receiving similar doses. Improved EDP-239 pharmacokinetics may also explain why a single 10-mg dose of EDP-239 resulted in a mean maximum reduction in GT1b HCV RNA of 3.9 log10 IU/ml, while three daily 10-mg doses of ledipasvir reduced GT1b HCV RNA by only a median maximum of 3.3 log10 IU/ml (15). Similarly, a single 100-mg EDP-239 dose reduced GT1a HCV RNA by 3.6 log10 IU/ml, compared to a reduction of 3.1 log10 IU/ml for three daily 90-mg doses of ledipasvir. However, given the small sample sizes of each dose cohort in this study, these differences may not be statistically significant. Due to the significant plasma exposures observed with EDP-239 monotherapy, it is expected that the NS5A inhibitor will also be efficacious in patients infected with HCV genotypes 4, 5, or 6 and potentially in patients infected with HCV genotypes 2 and 3.
When EDP-239 was tested in combination with other DAA or HTA compounds, the inhibition of replicon replication was additive to synergistic, without evidence of antagonism or cytotoxicity. Persistent treatment of replicon cells with EDP-239 in combination with sofosbuvir or alisporivir demonstrated clear combination effects consistent with the additivity excess studies and suppressed the development of HCV resistance. These results support the contention that EDP-239 may be used in combination with DAA or HTA compounds in patients to effectively suppress chronic HCV infection.
We thank the patients for their participation in this study. We acknowledge the ENANTA Pharmaceuticals and Novartis chemistry departments for their compound synthesis contributions.
This study was supported by ENANTA Pharmaceuticals, Inc., and Novartis. All authors from Enanta and Novartis were employees of Enanta and Novartis at the time the research was completed.
We disclose the following commercial relationships with the indicated entities: Stefan Zeuzem discloses Abbvie, BMS, Gilead, Janssen, and Merck/MSD; Fred Poordad discloses Abbvie, Achillion Pharmaceuticals, Anadys Pharmaceuticals, Biolex Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead Sciences, GlaxoSmithKline, GlobeImmune, Idenix Pharmaceuticals, Idera Pharmaceuticals, Intercept Pharmaceuticals, Janssen, Medarex, Medtronic, Merck, Novartis, Santaris Pharmaceuticals, Scynexis Pharmaceuticals, Vertex Pharmaceuticals, ZymoGenetics, Kadmon, Onyx/Bayer, Salix, and Tibotec/Janssen; Peter Buggisch discloses Abbott, AbbVie, BMS, Falk, Gilead, Janssen, Merck, Merz, MSD, Novartis, and Roche; Eric Lawitz discloses AbbVie, Achillion, Regulus, Theravance, Enanta, Idenix, Janssen, Merck & Co., Novartis, Gilead, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Intercept, Nitto Denko, and Salix; and Terry D. Box discloses Gilead, AbbVie, Salix, Bristol-Myers Squibb, Janssen, Merck & Co., Intercept, Idenix, Boehringer Ingelheim, Sundise, and Ikaria.
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
For a companion article on this topic, see doi:10.1128/AAC.00815-16.